Autolus Therapeutics plc Q2 2025 Earnings Recap

AUTL Q2 2025 August 12, 2025

Get alerts when AUTL reports next quarter

Autolus Therapeutics reported a strong second quarter with $20.9 million in product sales for Obe-cel, demonstrating solid momentum in its commercial launch and expanding market access potential.

Earnings Per Share Beat

$-0.18 vs $-0.24 est.

+25.0% surprise

Revenue Miss

20923000 vs 21078250 est.

-0.7% surprise

Market Reaction

1-Day +0.54%

5-Day -2.72%

30-Day -22.28%

See AUTL alongside your other holdings

Add to your portfolio — free

Key Takeaways

Generated $20.9 million in product sales in Q2, bringing YTD total to $29.9 million.
Expanded to 46 authorized treatment centers in the U.S. with 90% medical lives covered.
Achieved permanent HCPCS code effective July 1, 2025, aiding reimbursement processes despite initial patient enrollment slowdowns.
Expecting the Phase I results of OviCel's pediatric study by year-end, with plans to broaden its application.
R&D expenses decreased to $27.4 million, reflecting strategic shifts as commercial manufacturing scales up.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit AUTL on AllInvestView.

Next Q3 2025